Content about Mipomersen

January 30, 2013

The Food and Drug Administration has approved a new drug for treating a rare cholesterol disorder, the agency said.

SILVER SPRING, Md. — The Food and Drug Administration has approved a new drug for treating a rare cholesterol disorder, the agency said.

The FDA announced the approval of Kynamro (mipomersen sodium), made by Genzyme for the treatment of homozygous familial hypercholesterolemia, or HoFH. Kynamro has been approved as an orphan drug, a designation the FDA gives to drugs that treat diseases affecting fewer than 200,000 people.

August 5, 2010

Biotech company Genzyme and Isis Pharmaceuticals have finished late-stage clinical trials of a cholesterol-lowering drug,...

March 7, 2010

Bristol-Myers Squibb has paid Isis Pharmaceuticals a $6 million milestone payment for regulatory approval to...

February 9, 2010

A drug for treating a genetic cholesterol disorder decreased levels of “bad” LDL cholesterol in...